Monoclonal antibody significantly reduces nasal polyps and need for surgery in Phase 3 clinical trial

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, and quality of life. Epithelial barrier dysfunction and type 2 inflammatory responses drive disease progression. Treatments such as intranasal glucocorticoids and sinus surgery provide limited long-term relief and fail to address the underlying inflammatory mechanisms.